Nuvectis Pharma, Inc.
NVCT
$6.49
-$0.38-5.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 57.94% | -3.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.44% | -13.66% | |||
| Operating Income | -18.44% | 13.66% | |||
| Income Before Tax | -18.79% | 14.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.79% | 14.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.79% | 14.66% | |||
| EBIT | -18.44% | 13.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -10.85% | 23.99% | |||
| Normalized Basic EPS | -10.89% | 24.01% | |||
| EPS Diluted | -10.85% | 23.99% | |||
| Normalized Diluted EPS | -10.89% | 24.01% | |||
| Average Basic Shares Outstanding | 7.17% | 12.27% | |||
| Average Diluted Shares Outstanding | 7.17% | 12.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||